Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaxis completes Phase III bronchiectasis trial
This 12-month treatment period was an open label extension to a three- month efficacy trial which has already reported, showing that Bronchitol improved quality of life and mucus
This 12-month treatment period was an open label extension to a three- month efficacy trial which has already reported, showing that Bronchitol improved quality of life and mucus
The license is based on a suite of issued and pending Johns Hopkins University patents covering imprinting abnormalities of the insulin-like growth factor 2 gene (IGF2). Orion’s simple
This Phase II study was designed to assess the pharmacokinetics, safety and efficacy of MTR-106 tablets in female patients suffering from migraine without aura. The study population consisted
The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm. The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in allergic rhinitis
Sorin’s innovative vascular peripheral products are used by vascular surgeons and interventional radiologists for the treatment of peripheral arterial disease. As part of its acquisition, Datascope has also
Lupin’s Ramipril capsules are the AB-rated generic equivalent of King Pharmaceutical’s Altace capsules, indicated for the treatment of hypertension. On June 5, 2008, in an effort to restrict
Microbix had intended to spin off its own urokinase assets into a new private company, Klarogen Biotherapeutics, which would have purchased the urokinase assets of ImaRx. But ImaRx
The assets to be acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch system, the first diagnostic test to
The primary objective of the Phase Ib dose-escalation trial is to determine the safety and tolerability of a 72-hour continuous infusion of PX-12 given on the first three
Under the terms of the agreement Noxxon grants Lilly an exclusive worldwide license to a novel preclinical Spiegelmer, and will use its Spiegelmer technology to identify follow-on inhibitors.